Bevacizumab treatment of meningeal melanoma metastases

• Published in: Journal of translational medicine Vol. 18; no. 1; pp. 13 - 12
• Main Authors: Simonsen, Trude G, Gaustad, Jon-Vidar, Rofstad, Einar K
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.01.2020; BioMed Central; BMC
• Subjects: Adult; Angiogenesis; Angiogenesis inhibitors; Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Animals; Antiangiogenic agents; Antiangiogenic therapy; Antiangiogenics; Antibodies; Antineoplastic agents; Bevacizumab; Bevacizumab - pharmacology; Bevacizumab - therapeutic use; Brain; Brain cancer; Brain research; Cancer metastasis; Cancer treatment; Central nervous system diseases; Cerebrum; Chemical compounds; Drug therapy; Endothelial growth factors; Experiments; Female; Gene expression; Genes; Genetic research; Health aspects; Humans; Immune checkpoint inhibitors; Immunotherapy; Inhibitors; Inoculation; Interleukin 8; Laboratory animals; Medical prognosis; Medical research; Melanoma; Melanoma - drug therapy; Meningeal metastasis; Meningeal Neoplasms - drug therapy; Meningeal Neoplasms - secondary; Meninges; Metastases; Metastasis; Mice; Mice, Inbred BALB C; Monoclonal antibodies; Neovascularization, Pathologic - drug therapy; Novels; Patients; Polyclonal antibodies; Polymerase chain reaction; Skin cancer; Survival; Targeted cancer therapy; Time; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A; VEGF; Norway; New York; United States > US; Switzerland; Meningeal metastasis; Antiangiogenic therapy; VEGF; Melanoma; Bevacizumab
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-020-02212-3

Melanoma patients with metastatic growth in the meninges have poor prognosis and few treatment options. Although treatment with BRAF inhibitors or immune checkpoint inhibitors has provided promising results, most patients with advanced melanoma are resistant to these treatments and develop severe side effects. Novel treatment strategies are needed for patients with meningeal melanoma metastases, and the potential of antiangiogenic therapy was investigated in this preclinical study. Two GFP-transfected melanoma models (A-07 and D-12) differing substantially in VEGF-A expression were included in the study, and the anti-VEGF-A antibody bevacizumab was used as therapeutic agent. Meningeal metastases were initiated in BALB/c nu/nu mice by intracranial inoculation of melanoma cells, and bevacizumab treatment was given twice a week in i.p. doses of 10 mg/kg until the mice became moribund. Therapeutic effects were evaluated by determining tumor host survival time, assessing tumor growth and angiogenic activity by quantitative analyses of histological preparations, and measuring the expression of angiogenesis-related genes by quantitative PCR. Meningeal A-07 melanomas showed higher expression of VEGF-A than meningeal D-12 melanomas, whereas the expression of ANGPT2 and IL8, two important angiogenesis drivers in melanoma, was much higher in D-12 than in A-07 tumors. Bevacizumab treatment inhibited tumor angiogenesis and prolonged host survival in mice with A-07 tumors but not in mice with D-12 tumors. Meningeal A-07 tumors in bevacizumab-treated mice compensated for the reduced VEGF-A activity by up-regulating a large number of angiogenesis-related genes, including ANGPT2 and its receptors TIE1 and TIE2. Melanoma cells migrated from meningeal tumors into the cerebrum, where they initiated metastatic growth by vessel co-option. In the A-07 model, the density of cerebral micrometastases was higher in bevacizumab-treated than in untreated mice, either because bevacizumab treatment increased mouse survival or induced increased tumor gene expression. The development of antiangiogenic strategies for the treatment of meningeal melanoma metastases is a challenging task because the outcome of treatment will depend on the angiogenic signature of the tumor tissue, treatment-induced alterations of the angiogenic signature, and the treatment sensitivity of metastatic lesions in other intracranial sites.